Tox-Database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition

BMC Clinical Pharmacology

Miłosz Polak¹  Anna Glinka¹  Barbara Wiśniowska¹  Sebastian Polak¹ 

[1] Unit of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Pharmacy Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Krakow, Poland

关键词: IC50;    L-type calcium current;    Rapid potassium current;    Slow potassium current;    Sodium current;    Cardiotoxicity;    In vitro data;   

Others  :  860750
DOI  :  10.1186/2050-6511-13-6

 received in 2012-01-20, accepted in 2012-08-13,  发布年份 2012

【 摘 要 】

Background

Drugs safety issues are now recognized as being factors generating the most reasons for drug withdrawals at various levels of development and at the post-approval stage. Among them cardiotoxicity remains the main reason, despite the substantial effort put into in vitro and in vivo testing, with the main focus put on hERG channel inhibition as the hypothesized surrogate of drug proarrhythmic potency. The large interest in the IKr current has resulted in the development of predictive tools and informative databases describing a drug's susceptibility to interactions with the hERG channel, although there are no similar, publicly available sets of data describing other ionic currents driven by the human cardiomyocyte ionic channels, which are recognized as an overlooked drug safety target.

Discussion

The aim of this database development and publication was to provide a scientifically useful, easily usable and clearly verifiable set of information describing not only IKr (hERG), but also other human cardiomyocyte specific ionic channels inhibition data (IKs, INa, ICa).

Summary

The broad range of data (chemical space and in vitro settings) and the easy to use user interface makes tox-database.net a useful tool for interested scientists.

Database URL

http://tox-database.net. webcite

【 授权许可】

   
2012 Polak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004, 3(8):711-715.
• [2]Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer J: Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Care Res 2004, 55(4):543-550.
• [3]Glessner MR, Heller DA: Changes in related drug class utilization after market withdrawal of cisapride. Am J Manag Care 2002, 8(3):243-250.
• [4]National Research Council (U.S.): Toxicity testing in the 21st century a vision and a strategy. National Academies Press, Washington, DC; 2007. [http://site.ebrary.com/id/10197076 webcite.]
• [5]Drug Discovery Today.com. [http://www.drugdiscoverytoday.com/view/22374/horizon-2020-a-new-research-framework-for-developing-and-sharing-knowledge/ webcite]
• [6]Sushko I, Novotarskyi S, Körner R, Pandey AK, Rupp M, Teetz W, Brandmaier S, Abdelaziz A, Prokopenko VV, Tanchuk VY, Todeschini R, Varnek A, Marcou G, Ertl P, Potemkin V, Grishina M, Gasteiger J, Schwab C, Baskin II, Palyulin VA, Radchenko EV, Welsh WJ, Kholodovych V, Chekmarev D, Cherkasov A, Aires-De-Sousa J, Zhang Q-Y, Bender A, Nigsch F, Patiny L, et al.: Online chemical modeling environment (OCHEM): Web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des 2011, 25(6):533-554.
• [7]Kavlock R, Dix D: Computational toxicology as implemented by the U.S. EPA: Providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J Toxicol Environ Health B Crit Rev 2010, 13(2–4):197-217.
• [8]Hishigaki H, Kuhara S: hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds. Database 2011. Published online 2011 May 17
• [9]Du F, Yu H, Zou B, Babcock J, Long S, Li M: HERGCentral: A large database to store, retrieve, and analyze compound-human ether-à-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay and Drug Development Technologies 2011, 9(6):580-588.
• [10]Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A: The open-access dataset for in silico cardiotoxicity prediction system. Bioinformation 2011, 6(6):244-245.
• [11]Polak S, Wisniowska B, Glinka A, Fijorek K, Mendyk A: Slow delayed rectifying potassium current (IKs) – analysis of the in vitro inhibition data and predictive model development. J Appl Toxicol 2012 Feb 14. Epub ahead of print
• [12]: The Innovative Medicines Initiative. [http://www.imi.europa.eu/ webcite]
• [13]Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME: Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003, 78(12):1479-87.
• [14]Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL, Schwartz PJ: Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation 2007, 115(3):361-367.
• [15]Burke A, Creighton W, Mont E, Li L, Hogan S, Kutys R, Fowler D, Virmani R: Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation 2005, 112(6):798-802.
• [16]Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM: A common polymorphism in SCN5A is associated with lone atrial fibrillation. Clin Pharmacol Ther 2007, 81(1):35-41.
• [17]Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, Guicheney P: D.E.S.I.R. Study Group. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur J Hum Genet 2005, 13(11):1213-1222.
• [18]Marjamaa A, Newton-Cheh C, Porthan K, Reunanen A, Lahermo P, Väänänen H, Jula A, Karanko H, Swan H, Toivonen L, Nieminen MS, Viitasalo M, Peltonen L, Oikarinen L, Palotie A, Kontula K, Salomaa V: Common candidate gene variants are associated with QT interval duration in the general population. J Intern Med 2009, 265(4):448-58.
• [19]The International Conference on Harmonisation: S7B guidline: Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation). Human Pharmaceuticals; 2005. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129121.htm webcite
• [20]Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102(10):1178-1185.
• [21]Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002, 297(5585):1333-1336.
• [22]ten Tusscher KH, Noble D, Noble PJ, Panfilov AV: A model for human ventricular tissue. Am J Physiol Heart Circ Physiol 2004, 286(4):H1573-1589.
• [23]Tester DJ, Ackerman MJ: Sudden infant death syndrome: how significant are the cardiac channelopathies? Cardiovasc Res 2005, 67(3):388-396.
• [24]Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, Nademanee K, Brugada R, Brugada J, Veerakul G, Li H, Bowles NE, Brugada P, Antzelevitch C, Towbin JA: Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002, 11(3):337-345.
• [25]Yang P, Koopmann TT, Pfeufer A, Jalilzadeh S, Schulze-Bahr E, Kääb S, Wilde AA, Roden DM, Bezzina CR: Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet 2008, 16(3):350-357.
• [26]Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, Keating MT: Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 2005, 102(23):8089-8096.
• [27]Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, Tager-Flusberg H, Priori SG, Sanguinetti MC, Keating MT: Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119(1):19-31.
• [28]Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisle BP, Anderson CL, January CT: Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol 2004, 286(6):H2434-2441.
• [29]Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, Koopmann TT, Bhuiyan ZA, Wilders R, Mannens MM, Tan HL, Luft FC, Schunkert H, Wilde AA: A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003, 59(1):27-36.
• [30]Cordeiro JM, Brugada R, Wu YS, Hong K, Dumaine R: Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 2005, 67(3):498-509.
• [31]Koo SH, Ho WF, Lee EJ: Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore. Br J Clin Pharmacol 2006, 61(3):301-308.
• [32]Laitinen P, Fodstad H, Piippo K, Swan H, Toivonen L, Viitasalo M, Kaprio J, Kontula K: Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects. Hum Mutat 2000, 15(6):580-581.
• [33]Larsen LA, Andersen PS, Kanters J, Svendsen IH, Jacobsen JR, Vuust J, Wettrell G, Tranebjaerg L, Bathen J, Christiansen M: Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. Clin Chem 2001, 47(8):1390-1395.
• [34]Lin Z, Li Z, Yafei L, Xiangyu M: MinK gene G112A polymorphisms and atrial fibrillation: a Meta-analysis. Journal of Medical Colleges of PLA 2009, 24:198-207.
• [35]Männikkö R, Overend G, Perrey C, Gavaghan CL, Valentin JP, Morten J, Armstrong M, Pollard CE: Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. Br J Pharmacol 2010, 159(1):102-114.
• [36]Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004, 82(3):182-188.
• [37]Pietilä E, Fodstad H, Niskasaari E, Laitinen PPJ, Swan H, Savolainen M, Kesäniemi YA, Kontula K, Huikuri HV: Association between HERG K897T polymorphism and QT interval in middle-aged Finnish women. J Am Coll Cardiol 2002, 40(3):511-514.
• [38]Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97(2):175-87.
• [39]Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baró I, Wilde AA: Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004, 109(20):2394-2397.
• [40]Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA: Mutations in the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart 2004, 90(12):1487-1488.
• [41]Akyol M, Jalilzadeh S, Sinner MF, Perz S, Beckmann BM, Gieger C, Illig T, Wichmann HE, Meitinger T, Kääb S, Pfeufer A: The common non-synonymous variant G38S of the KCNE1-(minK)-gene is not associated to QT interval in Central European Caucasians: results from the KORA study. Eur Heart J 2007, 28(3):305-309.
• [42]The ionic current inhibition database. [www.tox-database.net webcite]
• [43]Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D: Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 2011, 91(1):53-61.
• [44]Towart R, Linders JTM, Hermans AN, Rohrbacher J, van der Linde HJ, Ercken M, Cik M, Roevens P, Teisman A, Gallacher DJ: Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening? J Pharmacol Toxicol Meth 2009, 60(1):1-10.
• [45]Mirams GR, Davies MR, Cui Y, Kohl P, Noble D: Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol 2012. May 9 x. [Epub ahead of print]
• [46]Wisniowska B, Mendyk A, Fijorek K, Glinka A, Polak S: Predictive model for the L-type channel inhibition - multichannel block in QT prolongation risk assessment. J Appl ToxicolAccepted for publication